Literature DB >> 15354394

Congruent deterioration of complex and simple movements in patients with Huntington's disease.

C Saft1, J Andrich, N M Meisel, H Przuntek, Th Müller.   

Abstract

Rating scales and assessment of simple and complex movements may reflect severity of Huntington's disease (HD). Objectives of our study were to compare scored HD symptoms and outcomes of instrumental tests, which demand for simple (tapping) and complex (peg insertion) movement series, in controls and subjects in various HD stages and to correlate them to each other. Motor test outcomes were significantly worsened in previously untreated and treated HD patients in comparison with HD gene carriers and controls. Peg insertion- and tapping results significantly correlated with the scored HD symptoms. Significant associations appeared between both motor test results in the controls, the previously untreated- and treated HD patients. Results of both instrumental tasks represent no specific diagnostic marker of HD, but the significant associations between both motor test outcomes indicate, that a parallel progress of deterioration of complex and simple movement abilities occurs after start of HD.

Entities:  

Mesh:

Year:  2004        PMID: 15354394     DOI: 10.1007/978-3-7091-0579-5_11

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  4 in total

1.  Assessment of simple movements and progression of Huntington's disease.

Authors:  Jürgen Andrich; Carsten Saft; Natalie Ostholt; Thomas Müller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04       Impact factor: 10.154

2.  A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data.

Authors:  Christian Beste; Ann-Kathrin Stock; Vanessa Ness; Rainer Hoffmann; Carsten Lukas; Carsten Saft
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

3.  Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.

Authors:  Carsten Saft; Thorsten Lauter; Peter H Kraus; Horst Przuntek; Juergen E Andrich
Journal:  BMC Neurol       Date:  2006-02-28       Impact factor: 2.474

4.  Rivastigmine in the treatment of patients with Alzheimer's disease.

Authors:  Thomas Müller
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.